4 news items
Theratechnologies Says Sudocetaxel Zendusortide ASCO 2024 Presentation Shows Signs Of Long-Term Efficacy And Manageable Safety Profile In Patients With Solid Tumors
THTX
23 May 24
Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
THTX
23 May 24
), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced Phase 1 data demonstrating signs of long-term efficacy
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
THTX
2 May 24
long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
THTX
10 Apr 24
such as enrollments and unique patients, we are on track to achieve and even surpass our long-term objectives. As anticipated during our recent fourth quarter
- Prev
- 1
- Next